secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001104659-23-089897
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconova reports Q2 2023 net loss of $4.3M; cash $29.7M; pipeline updates for narazaciclib and rigosertib
--------------------------------------------------------------------------------

- Net loss of $4.3M ($0.20 per share) vs $4.0M ($0.19) in Q2 2022.
- Cash $29.7M as of June 30, 2023; sufficient into Q2 2024.
- Topline results from Phase 1/2 narazaciclib studies expected in Q4 2023.
- Plans registrational trial for rigosertib in RDEB-SCC after constructive FDA Type B meeting in June.
- R&D expense $2.5M, G&A $2.2M for Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465923089897/0001104659-23-089897-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465923089897/tm2323468d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-089897

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer